All In Biotech

Drug Trial Radar · NCT04429334

Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features

Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Sep 23, 2020

Primary completion

May 20, 2022

Study completion Jun 22, 2022

Sponsor

Lead sponsor
InotremIndustry
Sponsor type
Industry
First posted
Jun 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, in which one dose of nangibotide will be tested versus placebo. All patients with a diagnosis of COVID-19, and a requirement for respiratory support will be considered for study participation. The applicable local requirements for informed consent will be followed. Where permissible, an emergency consent procedure will be followed for patients unable to provide consent by themselves. All potential study patients will receive standard of care treatment throughout the study. Patients will receive a continuous intravenous (i.v.) infusion of nangibotide at 1.0 mg/kg/h or a matching placebo. Treatment with study drug must be initiated as early as possible but no later than 48 hours after the initiation of ventilatory support (Patients will be treated for 5 days or until discharge from critical care, whichever is sooner). Follow-up visits will be performed on days 8 and 14. The end of study visit is at day 28. A further follow up visit will be undertaken on day 60.

Conditions

  • COVID19

Interventions

  • nangibotideDrug

    nangibotide 1.0 mg/kg/h

  • placeboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events until day 28Time frame: 28 days
  2. Clinical Status (7-point Ordinal Scale) assessed at Day 28Time frame: 28 days

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinique universitaire Saint-Luc

    Brussels, Belgium

  • Ziekenhuis Oost-Limburg

    Genk, Belgium

  • CHU Angers

    Angers, France

  • Centre hospitalier Victor Dupouy

    Argenteuil, France

  • Centre Hospitalier Germont et Gauthier

    Béthune, France

  • CHU Dijon - Bourgogne - Hôpital François Mitterrand

    Dijon, France

  • CHD Site la Roche sur Yon, les Oudairies

    La Roche-sur-Yon, France

  • Centre hospitalier le Manas

    Le Mans, France

  • Centre Hospitalier Universitaire Dupuytren

    Limoges, France

  • Centre hospitalier de Melun

    Melun, France

  • Hôpital Saint Eloi CHU Montpellier

    Montpellier, France

  • Réanimation Médicale, Hôpital Central

    Nancy, France

  • Hôpital Dieu - CHU Nanates

    Nantes, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Civil - Nouvel Hôpital civil

    Strasbourg, France

  • CHRU - Hôpital Bretonneau

    Tours, France

  • Hôpital Franch-Comté Site Trevenans

    Trévenans, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.